These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29293676)

  • 1. Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
    Kondili LA; Gaeta GB; Ieluzzi D; Zignego AL; Monti M; Gori A; Soria A; Raimondo G; Filomia R; Di Leo A; Iannone A; Massari M; Corsini R; Gulminetti R; Gatti Comini A; Toniutto P; Dissegna D; Russo FP; Zanetto A; Rumi MG; Brancaccio G; Danieli E; Brunetto MR; Weimer LE; Quaranta MG; Vella S; Puoti M
    PLoS One; 2018; 13(1):e0190803. PubMed ID: 29293676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction: Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon.
    Gambato M; Caro-Pérez N; González P; Cañete N; Mariño Z; Lens S; Bonacci M; Bartres C; Sánchez-Tapias JM; Carrión JA; Forns X; Juan M; Pérez-Del-Pulgar S; Londoño MC
    PLoS One; 2017; 12(1):e0170913. PubMed ID: 28107531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction: Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications.
    Boff da Costa R; Boff Costa M; Longo L; Miotto DE; Hirata Dellavia G; Trucollo Michalczuk M; Alvares-da-Silva M
    PLoS One; 2022; 17(5):e0269049. PubMed ID: 35604903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort.
    Höner Zu Siederdissen C; Maasoumy B; Marra F; Deterding K; Port K; Manns MP; Cornberg M; Back D; Wedemeyer H
    Clin Infect Dis; 2016 Mar; 62(5):561-7. PubMed ID: 26611779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
    De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
    J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PITER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy.
    Kondili LA; Vella S;
    Dig Liver Dis; 2015 Sep; 47(9):741-3. PubMed ID: 26138800
    [No Abstract]   [Full Text] [Related]  

  • 7. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of hepatitis C virus--2012: a real breakthrough].
    Zuckerman E
    Harefuah; 2012 Dec; 151(12):699-704, 719. PubMed ID: 23330264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients.
    Ueda Y; Uemoto S
    Transplantation; 2016 Jan; 100(1):54-60. PubMed ID: 26335914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.
    Florian J; Mishra P; Arya V; Harrington P; Connelly S; Reynolds KS; Sinha V
    Clin Pharmacol Ther; 2015 Oct; 98(4):394-402. PubMed ID: 26179495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid progression of antiviral treatments of chronic hepatitis C virus infection.
    Pol S; Corouge M; Mallet V; Sogni P
    Minerva Gastroenterol Dietol; 2013 Jun; 59(2):161-72. PubMed ID: 23831907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment.
    Spaan M; van Oord G; Kreefft K; Hou J; Hansen BE; Janssen HL; de Knegt RJ; Boonstra A
    J Infect Dis; 2016 Jan; 213(2):216-23. PubMed ID: 26223768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents.
    Kishta SS; Kishta SA; El-Shenawy R
    F1000Res; 2016; 5():223. PubMed ID: 27583130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C.
    Wong JB; Davis GL; McHutchison JG; Manns MP; Albrecht JK;
    Am J Gastroenterol; 2003 Nov; 98(11):2354-62. PubMed ID: 14638334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging treatments for chronic hepatitis C.
    Hayes CN; Chayama K
    J Formos Med Assoc; 2015 Mar; 114(3):204-15. PubMed ID: 25300586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic HCV genotype 1 coinfection.
    Boesecke C; Rockstroh JK
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.
    Rodríguez-Torres M
    Curr Opin Infect Dis; 2013 Feb; 26(1):50-7. PubMed ID: 23242341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A; Tornai I; Szalay F
    Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C.
    Chu PS; Nakamoto N; Taniki N; Ojiro K; Amiya T; Makita Y; Murata H; Yamaguchi A; Shiba S; Miyake R; Katayama T; Ugamura A; Ikura A; Takeda K; Ebinuma H; Saito H; Kanai T
    PLoS One; 2017; 12(6):e0179096. PubMed ID: 28617830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.